A third dose of the Pfizer-BioNTech vaccine – the so-called booster – should neutralize the new Omicron variant of the coronavirus.
Both pharmaceutical companies announced this on Wednesday based on their own lab research. Still, they are working on an adapted vaccine, which should be ready by March.
Pfizer-BioNTech conducted lab tests showing that a booster shot can detect 25 times more antibodies. That offers the same protection against serious illness as two doses with the previous variants of the coronavirus, it sounds.
These are preliminary data, and further research is underway.
But with this outcome, the pharmaceutical companies are arguing for a booster shot because they also admit that two doses of the current vaccine do not offer sufficient protection against the Omicron variant.